Whole inactivated SIV virion vaccines with functional envelope glycoproteins: Safety, immunogenicity, and activity against intrarectal challenge

J. D. Lifson; M. Piatak; J. L. Rossio; J. Bess; E. Chertova; D. Schneider; R. Kiser; V. Coalter; B. Poore; R. Imming; R. C. Desrosiers; L. E. Henderson; L. O. Arthur

doi:10.1034/j.1600-0684.2002.02007.x

Whole inactivated SIV virion vaccines with functional envelope glycoproteins: Safety, immunogenicity, and activity against intrarectal challenge

J. D. Lifson, M. Piatak, J. L. Rossio, J. Bess, E. Chertova, D. Schneider, R. Kiser, V. Coalter, B. Poore, R. Imming, R. C. Desrosiers, L. E. Henderson, L. O. Arthur

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

A novel type of whole inactivated simian immunodeficiency virus (SIV) virion vaccine immunogen with functional envelope glycoproteins was evaluated, without adjuvant, in rhesus macaques. Immunogens included purified inactivated virions of SIVmac239, a designed mutant of SIVmac239 with gp120 carbohydrate attachment sites deleted (SIVmac239 g4,5), and SIVmneE11S. The vaccines were noninfectious, safe, and immunogenic, inducing antibody responses and cellular responses, including responses by CD8+ lymphocytes. Interpretation of protective efficacy following intrarectal challenge was complicated by incomplete take of the challenge in some SIV naïve controls.

Original language	English (US)
Pages (from-to)	205-216
Number of pages	12
Journal	Journal of medical primatology
Volume	31
Issue number	4-5
DOIs	https://doi.org/10.1034/j.1600-0684.2002.02007.x
State	Published - Aug 2002
Externally published	Yes

Keywords

Inactivated
SIV
Vaccine

ASJC Scopus subject areas

Animal Science and Zoology
veterinary(all)

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1034/j.1600-0684.2002.02007.x

Fingerprint Dive into the research topics of 'Whole inactivated SIV virion vaccines with functional envelope glycoproteins: Safety, immunogenicity, and activity against intrarectal challenge'. Together they form a unique fingerprint.

Cite this

Lifson, J. D., Piatak, M., Rossio, J. L., Bess, J., Chertova, E., Schneider, D., Kiser, R., Coalter, V., Poore, B., Imming, R., Desrosiers, R. C., Henderson, L. E., & Arthur, L. O. (2002). Whole inactivated SIV virion vaccines with functional envelope glycoproteins: Safety, immunogenicity, and activity against intrarectal challenge. Journal of medical primatology, 31(4-5), 205-216. https://doi.org/10.1034/j.1600-0684.2002.02007.x

Whole inactivated SIV virion vaccines with functional envelope glycoproteins : Safety, immunogenicity, and activity against intrarectal challenge. / Lifson, J. D.; Piatak, M.; Rossio, J. L.; Bess, J.; Chertova, E.; Schneider, D.; Kiser, R.; Coalter, V.; Poore, B.; Imming, R.; Desrosiers, R. C.; Henderson, L. E.; Arthur, L. O.

In: Journal of medical primatology, Vol. 31, No. 4-5, 08.2002, p. 205-216.

Research output: Contribution to journal › Article › peer-review

Lifson, JD, Piatak, M, Rossio, JL, Bess, J, Chertova, E, Schneider, D, Kiser, R, Coalter, V, Poore, B, Imming, R, Desrosiers, RC, Henderson, LE & Arthur, LO 2002, 'Whole inactivated SIV virion vaccines with functional envelope glycoproteins: Safety, immunogenicity, and activity against intrarectal challenge', Journal of medical primatology, vol. 31, no. 4-5, pp. 205-216. https://doi.org/10.1034/j.1600-0684.2002.02007.x

Lifson, J. D. ; Piatak, M. ; Rossio, J. L. ; Bess, J. ; Chertova, E. ; Schneider, D. ; Kiser, R. ; Coalter, V. ; Poore, B. ; Imming, R. ; Desrosiers, R. C. ; Henderson, L. E. ; Arthur, L. O. / Whole inactivated SIV virion vaccines with functional envelope glycoproteins : Safety, immunogenicity, and activity against intrarectal challenge. In: Journal of medical primatology. 2002 ; Vol. 31, No. 4-5. pp. 205-216.

@article{ecefebc7818a4bd1a24af8bd6b2a81b2,

title = "Whole inactivated SIV virion vaccines with functional envelope glycoproteins: Safety, immunogenicity, and activity against intrarectal challenge",

abstract = "A novel type of whole inactivated simian immunodeficiency virus (SIV) virion vaccine immunogen with functional envelope glycoproteins was evaluated, without adjuvant, in rhesus macaques. Immunogens included purified inactivated virions of SIVmac239, a designed mutant of SIVmac239 with gp120 carbohydrate attachment sites deleted (SIVmac239 g4,5), and SIVmneE11S. The vaccines were noninfectious, safe, and immunogenic, inducing antibody responses and cellular responses, including responses by CD8+ lymphocytes. Interpretation of protective efficacy following intrarectal challenge was complicated by incomplete take of the challenge in some SIV na{\"i}ve controls.",

keywords = "Inactivated, SIV, Vaccine",

author = "Lifson, {J. D.} and M. Piatak and Rossio, {J. L.} and J. Bess and E. Chertova and D. Schneider and R. Kiser and V. Coalter and B. Poore and R. Imming and Desrosiers, {R. C.} and Henderson, {L. E.} and Arthur, {L. O.}",

year = "2002",

month = aug,

doi = "10.1034/j.1600-0684.2002.02007.x",

language = "English (US)",

volume = "31",

pages = "205--216",

journal = "Journal of Medical Primatology",

issn = "0047-2565",

publisher = "Blackwell Munksgaard",

number = "4-5",

}

TY - JOUR

T1 - Whole inactivated SIV virion vaccines with functional envelope glycoproteins

T2 - Safety, immunogenicity, and activity against intrarectal challenge

AU - Lifson, J. D.

AU - Piatak, M.

AU - Rossio, J. L.

AU - Bess, J.

AU - Chertova, E.

AU - Schneider, D.

AU - Kiser, R.

AU - Coalter, V.

AU - Poore, B.

AU - Imming, R.

AU - Desrosiers, R. C.

AU - Henderson, L. E.

AU - Arthur, L. O.

PY - 2002/8

Y1 - 2002/8

N2 - A novel type of whole inactivated simian immunodeficiency virus (SIV) virion vaccine immunogen with functional envelope glycoproteins was evaluated, without adjuvant, in rhesus macaques. Immunogens included purified inactivated virions of SIVmac239, a designed mutant of SIVmac239 with gp120 carbohydrate attachment sites deleted (SIVmac239 g4,5), and SIVmneE11S. The vaccines were noninfectious, safe, and immunogenic, inducing antibody responses and cellular responses, including responses by CD8+ lymphocytes. Interpretation of protective efficacy following intrarectal challenge was complicated by incomplete take of the challenge in some SIV naïve controls.

AB - A novel type of whole inactivated simian immunodeficiency virus (SIV) virion vaccine immunogen with functional envelope glycoproteins was evaluated, without adjuvant, in rhesus macaques. Immunogens included purified inactivated virions of SIVmac239, a designed mutant of SIVmac239 with gp120 carbohydrate attachment sites deleted (SIVmac239 g4,5), and SIVmneE11S. The vaccines were noninfectious, safe, and immunogenic, inducing antibody responses and cellular responses, including responses by CD8+ lymphocytes. Interpretation of protective efficacy following intrarectal challenge was complicated by incomplete take of the challenge in some SIV naïve controls.

KW - Inactivated

KW - SIV

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0036694204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036694204&partnerID=8YFLogxK

U2 - 10.1034/j.1600-0684.2002.02007.x

DO - 10.1034/j.1600-0684.2002.02007.x

M3 - Article

C2 - 12390543

AN - SCOPUS:0036694204

VL - 31

SP - 205

EP - 216

JO - Journal of Medical Primatology

JF - Journal of Medical Primatology

SN - 0047-2565

IS - 4-5

ER -

Whole inactivated SIV virion vaccines with functional envelope glycoproteins: Safety, immunogenicity, and activity against intrarectal challenge

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this